National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).

490 total trials 50 currently recruiting 398 completed early-phase tilt top decile by trial count

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.

Top-decile sponsor footprint

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 74/100

398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

490 total, page 10 of 10

COMPLETED Phase 3

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

NCT00006398

COMPLETED Phase 3

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

NCT00004266

COMPLETED

History of Hepatitis C in Volunteer Blood Donors

NCT00001982

COMPLETED NA

Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy

NCT00004660

COMPLETED

Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome

NCT00001254

COMPLETED

The Treatment and Natural History of Acromegaly

NCT00001981

COMPLETED

Assessment of Sympathetic Nervous System Activity by Microneurography Recording Technique

NCT00341770

TERMINATED

Determination of Kidney Function

NCT00001978

COMPLETED

Treatment of Zollinger-Ellison Syndrome

NCT00001241

COMPLETED

Evaluating Patients With Abnormal Levels of Gastric Acid

NCT00001240

COMPLETED

Use of Biopsy Punch for Skin Biopsies for Fibroblasts Culturing

NCT00340912

COMPLETED Phase 2

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

NCT00001228

TERMINATED

Diagnosis and Treatment of Patients With Cystic Fibrosis

NCT00001223

COMPLETED Phase 2

Drug Therapy in Lupus Nephropathy

NCT00001212

COMPLETED NA

Diabetes Control and Complications Trial (DCCT)

NCT00360815

COMPLETED Phase 2

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

NCT00001191

COMPLETED

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

NCT00340132

COMPLETED Phase 2

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas

NCT00001165

COMPLETED

Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community

NCT00339482

TERMINATED Phase 2

Studies With 1,25-Dihydroxycholecalciferol

NCT00001151

COMPLETED Phase 2

Written Self-disclosure for Youth Abdominal Pain

NCT00062608

COMPLETED

Free-Living Physical Activity and Energy Expenditure

NCT00062998

COMPLETED

Medical and Surgical Treatment of Esophageal Reflux

NCT00061724

COMPLETED

ORWH:SCOR - Sex/Gender Factors Affecting Women's Health

NCT00068120

COMPLETED NA

Native Hawaiian Diabetes Intervention Program

NCT00006165

COMPLETED NA

Benefits and Risks of Newborn Screening for Cystic Fibrosis

NCT00014950

COMPLETED NA

Improving Medication Adherence in Comorbid Conditions

NCT00072891

COMPLETED NA

Comparison of Two Therapies for Upper Esophageal Sphincter (UES) Dysphagia

NCT00059670

COMPLETED Phase 2

Medical College of Georgia FitKid Project

NCT00061841

COMPLETED NA

African-American Diabetes Intervention Project

NCT00006160

COMPLETED

Exercise Amenorrhea Stress and Bone Health in Adolescents

NCT00441402

COMPLETED NA

Effectiveness of Primary Care Physicians in Delivering Weight Control Counseling

NCT00017706

COMPLETED NA

Impact of Non-Commercialism Policy in Seattle Schools

NCT00065000

COMPLETED

Cognition, Steroids, and Imaging in Cushings Disease

NCT00081341

COMPLETED NA

Diet and Physical Activity Interactions in Obesity

NCT00067964

COMPLETED NA

Depression In Juvenile Diabetics

NCT00005116

COMPLETED Phase 3

Computer Intervention for Prevention of Weight Regain

NCT00067145

COMPLETED

Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

NCT00059449

COMPLETED Phase 3

A Pilot Study of Diabetes Risk Reduction Program With WIC Mothers(The Special Supplemental Nutrition Program for Women, Infants, and Children) Overweight WIC Mothers

NCT00944060

COMPLETED Phase 3

Clinical Approaches to Ileal Pouch Dysfunction

NCT00293553

← Previous Page 10 of 10

Phase Distribution

PhaseTrial count
Phase 1 42
Phase 2 136
Phase 3 55
Phase 4 14

What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline

50 recruiting of 490 indexed (10% open); 398 completed (81%).

Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).

Top condition: Obesity (25 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide

Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 8%10%12%14%16%18% Total trials Recruiting share National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Beth Israel Deaconess Medical CenterFred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)H. Lee Moffitt Cancer Center and Research InstituteMirati TherapeuticsJames J. Peters Veterans Affairs Medical CenterCalifornia Pacific Medical Center Research InstituteNational Institute of Environmental Health Sciences (NIEHS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 490 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page

490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.

  • 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.